Skip to main content
RUNBEN BIOTECHNOLOGY CO., LTD. logo

RUNBEN BIOTECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 603193 ISIN · CNE100006DK5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 269 across all filing types
Latest filing 2024-04-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603193

About RUNBEN BIOTECHNOLOGY CO., LTD.

https://www.runben.com/

Runben Biotechnology Co., Ltd. focuses on the research, development, production, and distribution of personal care and household hygiene solutions. The company’s core product portfolio is categorized into mosquito repellents, infant and child care, and essential oil products. Key offerings include electric mosquito repellent liquids, botanical essential oil patches, and specialized skincare items such as moisturizing creams and cleansing products tailored for sensitive skin. Runben prioritizes the integration of biotechnology with natural formulations to ensure product safety and efficacy. By maintaining a strong emphasis on product innovation and quality control, the company serves a broad consumer base through integrated online and offline sales channels, positioning itself as a provider of health-oriented daily necessities for family environments.

Recent filings

Filing Released Lang Actions
润本生物技术股份有限公司2023年度审计报告
Regulatory Filings
2024-04-24 Chinese
关于2024年度使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company about its plan to use idle funds for cash management by investing in low-risk financial products. It details the investment amount, purpose, risk analysis, and approval procedures, including board and supervisory committee meetings. The document does not contain financial statements or detailed financial results but is a formal disclosure of a financing or capital management activity. It is not an annual or interim report, earnings release, or audit report. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management plans.
2024-04-24 Chinese
关于2023年第四季度主要经营数据的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the company's main operating data for the fourth quarter of 2023, including production, sales volume, revenue, and price changes of main products and raw materials. It is relatively short (1699 characters) and does not contain comprehensive financial statements or detailed financial analysis. It is a quarterly operational data disclosure rather than a full interim or quarterly financial report. The document is a regulatory announcement of quarterly operating data as required by the Shanghai Stock Exchange guidelines, not a full Interim/Quarterly Report (IR). Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not meet the criteria for a full financial report.
2024-04-24 Chinese
董事、监事、高级管理人员2023 年度薪酬发放情况及2024年度薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the remuneration (salary) payment situation for directors, supervisors, and senior management for the year 2023 and the remuneration plan for 2024. It details the salary schemes for these company officials and mentions internal company rules and approvals by the board and supervisory meetings. There is no financial statement or detailed financial report included, nor is it a report publication announcement. The content focuses specifically on compensation information for executives and directors, which fits the definition of Remuneration Information filings.
2024-04-24 Chinese
2023年度独立董事述职报告（郑怡玲）
Management Reports Classification · 95% confidence The document is titled as a "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's duties, attendance at board and shareholder meetings, participation in committees, oversight of related party transactions, appointment of auditors, and evaluation of financial and internal control reports for the year 2023. The content is a detailed management report on the independent director's activities and oversight during the fiscal year. It is not an announcement, certification, or a brief summary but a substantive report on management and governance activities. Therefore, it fits best under Management Reports (MDA).
2024-04-24 Chinese
申万宏源证券承销保荐有限责任公司关于润本生物技术股份有限公司首次公开发行网下配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal verification opinion issued by the underwriting and sponsorship company regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It references regulatory approvals, share lock-up periods, shareholding changes, and compliance with securities regulations. The document does not contain financial statements or detailed financial performance data but rather focuses on the compliance and procedural aspects of share circulation post-IPO. The length is about 2800 characters, which is relatively short and the content is a formal opinion or verification rather than a full report. This fits the category of a Regulatory Filing (RNS), as it is a compliance and regulatory disclosure related to share circulation and lock-up release, not a full financial report or announcement of voting results, management changes, or capital updates.
2024-04-11 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.